GLP3 (also written GLP-3) is the informal name for retatrutide (LY3437943), Eli Lilly's investigational once-weekly injectable. It activates three receptors: GLP-1, GIP and glucagon. It is not FDA-approved. In the Phase 3 TRIUMPH-1 trial (NEJM 2026), adults with obesity on the 12 mg dose lost a mean of 25.0% of body weight at 80 weeks, compared with 3.9% on placebo. Lilly plans to submit a Biologics License Application to the FDA in Q1 2027.
| Names | Retatrutide, LY3437943; informally GLP3, GLP-3, "Reta" |
|---|---|
| Developer | Eli Lilly and Company |
| Mechanism | Triple agonist of the GLP-1, GIP and glucagon receptors |
| How it was studied | Once-weekly subcutaneous injection, with dose escalation |
| Phase 2 result | 24.2% mean weight loss at 48 weeks, 12 mg (NEJM 2023) |
| Phase 3 result | 25.0% mean weight loss at 80 weeks, 12 mg, vs 3.9% placebo (TRIUMPH-1, NEJM 2026) |
| Regulatory status | Investigational. Not FDA-approved. BLA submission planned for Q1 2027 |
GLP3-R, GLP-3 RT, "Reta" and GLP3-B: what the names mean
"GLP3" is shorthand, not an official drug name. There is no hormone called GLP-3 and no GLP-3 receptor; the nickname places retatrutide one step beyond GLP-1 drugs such as semaglutide and dual GLP-1/GIP drugs such as tirzepatide.
- GLP3-R, GLP-3 RT, GLP3 RT, R3T, "Reta": labels that research-peptide sellers commonly print on vials meant to contain retatrutide. These are marketing abbreviations, not regulatory names, and the products carrying them are sold as "research use only", not for human use. See the black-market warning for the purity and contamination risks.
- GLP3-B and similar capsule products: marketed as dietary supplements. They are not retatrutide. Retatrutide has only been studied as a once-weekly injection; no oral form has been tested in published trials, so a capsule sold as "GLP3" is not the molecule studied in the TRIUMPH program. See what GLP3-B is and what its sellers list as ingredients.
How retatrutide works
Retatrutide engages three receptors involved in energy balance and body-weight regulation:
- GLP-1 receptor: reduces appetite, slows gastric emptying and improves glycemic control. This is the pathway of semaglutide (Ozempic/Wegovy).
- GIP receptor: enhances insulin secretion and may contribute to fat mobilization. Tirzepatide (Mounjaro/Zepbound) adds this pathway to GLP-1.
- Glucagon receptor: associated in published studies with increased energy expenditure and hepatic fat oxidation. Semaglutide and tirzepatide, the incretin drugs FDA-approved for weight management, do not act on the glucagon receptor.
For receptor-binding detail, see retatrutide's mechanism of action.
What the clinical trials reported
Every figure below is a group average reported under trial conditions. None is an individual outcome or a result this site offers. Peer-reviewed figures count every randomized participant, including those who stopped treatment (the treatment-regimen, or intention-to-treat, estimand).
| Trial | Population | Duration | Mean weight loss (by dose) |
|---|---|---|---|
| Phase 2 (Jastreboff et al., NEJM 2023) | Adults with obesity, or overweight with a weight-related condition | 48 weeks | Up to 24.2% (12 mg) |
| TRIUMPH-1 (Phase 3, NEJM 2026) | Adults with obesity, without diabetes | 80 weeks | 17.6% (4 mg), 23.7% (9 mg), 25.0% (12 mg); placebo 3.9% |
| TRIUMPH-2 (Phase 3, Lancet 2026) | Adults with obesity or overweight and type 2 diabetes | 80 weeks | 11.9% (4 mg), 16.8% (9 mg), 18.8% (12 mg); placebo 5.1% |
| TRIUMPH-3 (Phase 3, Lilly topline) | Adults with severe obesity and established cardiovascular disease | 80 weeks | 21.6% (9 mg), 22.6% (12 mg); placebo 3.2% (participants who stayed on treatment) |
Lilly's earlier press releases quoted higher figures for participants who stayed on treatment (the efficacy estimand): 28.3% at 12 mg in TRIUMPH-1 and 20.8% in TRIUMPH-2. TRIUMPH-3 is not yet peer-reviewed, so only Lilly's on-treatment topline is available. The clinical trials page covers each study's design, and the week-by-week trial weight data shows how the averages changed over time.
GLP-1 vs GLP-3: semaglutide, tirzepatide and retatrutide
| Semaglutide | Tirzepatide | Retatrutide ("GLP-3") | |
|---|---|---|---|
| Receptors | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + glucagon |
| Brand names | Wegovy, Ozempic | Zepbound, Mounjaro | None (investigational) |
| FDA status | Approved for chronic weight management | Approved for chronic weight management | Not approved; BLA planned Q1 2027 |
| Pivotal weight-loss trial | 14.9% at 68 weeks, 2.4 mg (STEP 1) | 20.9% at 72 weeks, 15 mg (SURMOUNT-1) | 25.0% at 80 weeks, 12 mg (TRIUMPH-1) |
All three figures count every randomized participant, but the trials enrolled different populations over different durations, so they are not a head-to-head comparison. See the plain-language GLP-1 vs GLP-3 comparison or the full retatrutide vs semaglutide vs tirzepatide breakdown.
Is GLP3 safe? Reported side effects
Across the TRIUMPH trials, the most common adverse events were gastrointestinal (nausea, diarrhea, constipation and vomiting) and were generally mild to moderate. Dysesthesia, an abnormal skin sensation, was reported in a subset of TRIUMPH-1 participants and was usually mild. In TRIUMPH-1, Lilly reported discontinuation due to adverse events of 4.1% (4 mg), 6.9% (9 mg) and 11.3% (12 mg), vs 4.9% on placebo. In TRIUMPH-3 it was 9.8% (9 mg) and 13.5% (12 mg), vs 4.8%.
Long-term safety has not been established, and the trial safety data applies only to the pharmaceutical-grade compound used in those trials, not to unregulated products sold online. See is GLP3 safe? Side-effect rates from each trial and the contraindications reported for this drug class. Related evidence pages cover how doses were escalated in the trials and what is known about alcohol and retatrutide.
FDA status, availability and cost
Retatrutide is not FDA-approved and has no approved prescription price. Lilly plans to submit its Biologics License Application in Q1 2027; FDA review typically takes months after submission. Until then, the compound is available only to people enrolled in clinical trials. Products sold online as "retatrutide", "GLP3-R" or "GLP-3 RT" are labeled for research use only and are not approved for human use.
For general market pricing of the FDA-approved GLP-1 drugs, see what FDA-approved GLP-1 medications cost.